Skip to main content

Table 9 Outcome for biological markers: remaining

From: The clinical use of biomarkers as prognostic factors in Ewing sarcoma

Author

Year

Biomarker

Pt number

P

Craft et al, Eur J Cancer 33 (7), 1061-9[8]

1997

LDH

142

NS

Aparicio et al, Oncology 55, 20-6[9]

1998

LDH

116

0.001

Givens et al, Int J Oncol 14 (6), 1039-43[12]

1999

LDH

85

NS

Bacci et al, Oncol Rep 6 (4), 807-11[71]

1999

LDH

618

S

Luksch et al, Tumori 85 (2), 101-7[41]

1999

LDH

73

S

Bacci et al, J Clin Oncol 18, 4-11[13]

2000

LDH

359

0.0003

Matsunobu et al, Clin Cancer Res 10, 1003-12[29]

2004

LDH

21

NS

Bacci et al, Acta Oncol 45, 469-75[16]

2006

LDH

579

0.0005

Cheung et al, Clin Cancer Res 13 (23), 6978-83[32]

2007

LDH

28

0.99

Yabe et al, Oncol Rep 19 (1), 129-34[70]

2008

LDH

20

NS

Leavey et al, Pediatr Blood Cancer 51 (3), 334-8[18]

2008

LDH

262

0.0016

Xie et al, Chin J Cancer 29 (4), 420-4

2010

LDH

18

NS

Terrier et al, Eur J Cancer 31 (3), 307-14[36]

1995

Filigree pattern

315

0.044

Terrier et al, Eur J Cancer 31 (3), 307-14[36]

1995

Dark cells

315

0.043

Aparicio et al, Oncology 55, 20-6[9]

1998

Albumine levels

116

0.0006

Sollazzo et al, Tumori 85 (3), 167-73[56]

1999

c-myc

38

S

Ohali et al, Oncogene 23, 8997-9006[60]

2004

MTA1

20

0.003

Cheung et al, Clin Cancer Res 13 (23), 6978-83[32]

2007

NKX2-2

28

0.0017

Kikuta et al, Clin Cancer Res 15 (8), 2885-94[20]

2009

Nucleophosmin positivity

8

0.01

Meynet et al, Cancer Res 70 (9), 3730-8[55]

2010

Xg expression

97

0.047

  1. S: significant, NS: not significant